Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at ...
Even if a company is profitable, it doesn’t always mean it’s a great investment. Some struggle to maintain growth, face looming threats, or fail to reinvest ...
ANI Pharmaceuticals (NASDAQ:ANIP) reported first-quarter 2026 results that management said show continued progress in its effort to “accelerat[e] our transformation into a leading rare disease company,” led by growth in Cortrophin Gel and ILUVIEN, contributions from a new intellectual property licen
Specialty pharmaceutical company ANI Pharmaceuticals (NASDAQ:ANIP) announced better-than-expected revenue in Q1 CY2026, with sales up 20.5% year on year to $...
Specialty pharmaceutical company ANI Pharmaceuticals (NASDAQ:ANIP) will be reporting earnings this Friday before market open. Here’s what you need to know. A...
Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at ...
Wrapping up Q4 earnings, we look at the numbers and key takeaways for the pharmaceuticals stocks, including Elanco (NYSE:ELAN) and its peers. The pharmaceuti...
While strong cash flow is a key indicator of stability, it doesn’t always translate to superior returns. Some cash-heavy businesses struggle with inefficient...
Small-cap stocks can be incredibly lucrative investments because their lack of analyst coverage leads to frequent mispricings. However, these businesses (and...
What Happened? A number of stocks jumped in the afternoon session after the government announced a surprise increase in payment rates for Medicare Advantage ...
The Russell 2000 (^RUT) is packed with potential breakout stocks, thanks to its focus on smaller companies with high growth potential. However, smaller size ...
What a brutal six months it’s been for ANI Pharmaceuticals. The stock has dropped 22.2% and now trades at $73.90, rattling many shareholders. This may have i...
Wall Street has set ambitious price targets for the stocks in this article. While this suggests attractive upside potential, it’s important to remain skeptic...
As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results from Q4. Today, we are looking a...
While profitability is essential, it doesn’t guarantee long-term success. Some companies that rest on their margins will lose ground as competition intensifi...
Wrapping up Q4 earnings, we look at the numbers and key takeaways for the generic pharmaceuticals stocks, including Amneal (NASDAQ:AMRX) and its peers. The g...
As the Q4 earnings season wraps, let’s dig into this quarter’s best and worst performers in the generic pharmaceuticals industry, including ANI Pharmaceutica...
A number of stocks fell in the afternoon session after a surprisingly hot wholesale inflation report fueled investor concerns about persistent price pressures.
Specialty pharmaceutical company ANI Pharmaceuticals (NASDAQ:ANIP) announced better-than-expected revenue in Q4 CY2025, with sales up 29.6% year on year to $247.1 million. The company’s full-year revenue guidance of $1.09 billion at the midpoint came in 4.8% above analysts’ estimates. Its non-GAAP profit of $2.33 per share was 17.9% above analysts’ consensus estimates.
A stock with low volatility can be reassuring, but it doesn’t always mean strong long-term performance.
Investors who prioritize stability may miss out on higher-reward opportunities elsewhere.
